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in all genotypes (~30% in African Americans). Alinia
(nitazoxanide[NTZ]), an interferon inducer may increase
SVR in combination with PegIFN and RBV. Very rapid virologic
response (VRVR) deﬁned as undetectable HCVRNA 14 days
after initiation of combination therapy may predict even
higher SVR rates. We assessed NTZ in combination with
high-dose RBV and PegIFN alfa-2a in Hepatitis C treatment.
Methods: Prospective, open-label, pilot study of naı¨ve
patients with chronic hepatitis C GT1. 33 patients
were enrolled. Exclusions: uncontrolled diabetes mellitus,
decompensated cirrhosis etc. Patients received NTZ 500mg
bid for ﬁrst 2 weeks; RBV 800mg in AM and 600mg at night
added to NTZ for next 2 weeks; subcutaneous PegIFN alfa-2a
180mcg weekly added to RBV and NTZ at the same dose
(triple-regimen) for next 12 weeks. Patients who achieved
EVR continued PegIFN alfa-2a and RBV for the next 36 weeks
at the same dose. VRVR, Rapid Viral Response (RVR), Early
Viral response (EVR), End Treament Viral Response (ETR),
and Sustained Viral Response (SVR) were assessed (COBAS
TaqMan HCV Test v2.0, Roche Diagnostics).
Results: Overall SVR 66.7% (22/33). Demographics:
Caucasian (n = 16, 48.5%), Hispanic (n = 6, 18.2%), African-
American (n = 5, 15.1%), and Asian (n = 6, 18.2%). Mean
BMI 27.9; mean HCVRNA-600,000 IU/ml; ﬁbrosis score-
F2 (48.5%). Growth factors were used to minimize
dose reductions. Adverse effects (AE): skin rash (27.3%);
neutropenia (51.5%); thrombocytopenia (39.4%); anemia
(48.5%); 6.1% discontinued treatment due to AE. None had
dose reductions.
Conclusion: This regimen of NTZ, high-dose RBV and PegIFN
alfa-2a enhances RVR over historical controls and offers an
improved SVR rate of 66.7% compared to 40.9% SVR rate in
GT1 from the recent IDEAL Study.
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To promote the diagnostic rate of HIV/AIDS complicated with
cytomegalovirus (CMV) viremia, enhance curative effects
and improve the prognosis. The clinical data in 249 cases of
HIV/AIDS patients hospitalized from Oct.2008 to Nov. 2009
have been collected and studied retrospectively, in which
we found that 43 HIV/AIDS patients have infected CMV.
Pathological detections have been analyzed from specimen
taken with gastroscope, ﬁbercoloscope, bronchoscope and
bronchoalveolar lavage ﬂuid (BALF). We also analyzed
association between cellular immunity and CMV-DNA levels.
We found that 43 patients (17.3%) have been diagnosed
as CMV viremia in accordance with positive results of
CMV pp65 antigen and CMV-DNA; 14 patients manifested
Figure 1. Retinitis.
Figure 2. CMV pneumonitis.
retinal bleeding or inﬁltration and 4 patients displayed
retinal ﬁbrosis; 1 patients have been diagnosed as CMV
pneumonitis according to pathological results from BALF;
No CMV esophagitis or colitis has been diagnosed in
these 43 patients. We also found the positive association
between low level of CD4+T lymphocytes and CMV-DNA
levels. The detections of CMV pp65 antigen and CMV-
DNA should be detected and anti-CMV treatment should
be taken in HIV/AIDS patients with less than 50/ul
of CD4+T lymphocytes. Ophthalmologic examination and
pathological detection in BALF are effective methods in
diagnosing CMV retinitis and pneumonitis.
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Background: HIV-1 genotypic-resistance is becoming
increasingly signiﬁcant in drug resistance monitoring.
However, many areas in some developing countries in Asia
still lack of such information due to its high running cost.
This is the ﬁrst study to determine the prevalence of
drug resistance mutations of reverse transcriptase (RT) and
protease (PR) genes and speciﬁc HIV-1 subtypes in North-
eastern part of Malaysia.
Methods: The genotypic resistance testing was performed
among 50 HIV-1 seropositive treated and treatment naı¨ve
subjects in Hospital Raja Perempuan Zainab 2, Kota Bharu.
The HIV-1 PR and RT genes were ampliﬁed from 140ml of
plasma-derived HIV-1 viral RNA via reverse transcription-
polymerase chain reaction and genotype determined via
DNA sequencing. Drug resistance mutations were analysed
using the Stanford HIV Sequence Resistance Database.
Results: CRF01_AE was found to be the dominant subtype
by both PR and RT genes in both antiretroviral treated and
naive patients (59.4%). B subtype was present to a much
lower level (21.9%), followed by CRF01_AE/B intersubtype
recombinant (18.8%). Fifteen percent of the treated and
0.06% naı¨ve patients had mutations associated with PIs.
The frequency of mutations associated with NRTIs and
NNRTIs resistance in treated patients was 40.6% and 34.4%,
respectively compared to 0.06% and 0.09% in naı¨ve patients.
